Programming of Influenza Vaccine Broadness and Persistence by Mucoadhesive Polymer-Based Adjuvant Systems

The development of an anti-influenza vaccine with the potential for cross-protection against seasonal drift variants as well as occasionally emerging reassortant viruses is essential. In this study, we successfully generated a novel anti-influenza vaccine system combining conserved matrix protein 2 (sM2) and stalk domain of hemagglutinin (HA2) fusion protein (sM2HA2) and poly-γ-glutamic acid (γ-PGA)–based vaccine adjuvant systems that can act as a mucoadhesive delivery vehicle of sM2HA2 as well as a robust strategy for the incorporation of hydrophobic immunostimulatory 3-O-desacyl-4′-monophosphoryl lipid A (MPL) and QS21. Intranasal coadministration of sM2HA2 and the combination adjuvant γ-PGA/MPL/QS21 (CA-PMQ) was able to induce a high degree of protective mucosal, systemic, and cell-mediated immune responses. The sM2HA2/CA-PMQ immunization was able to prevent disease symptoms, confering complete protection against lethal infection with divergent influenza subtypes (H5N1, H1N1, H5N2, H7N3, and H9N2) that lasted for at least 6 mo. Therefore, our data suggest that mucosal administration of sM2HA2 in combination with CA-PMQ could be a potent strategy for a broad cross-protective influenza vaccine, and CA-PMQ as a mucosal adjuvant could be used for effective mucosal vaccines.

[1]  H. Son,et al.  Heterosubtypic protective immunity against widely divergent influenza subtypes induced by fusion protein 4sM2 in BALB/c mice , 2014, Virology Journal.

[2]  H. Son,et al.  The highly conserved HA2 protein of the influenza A virus induces a cross protective immune response. , 2013, Journal of virological methods.

[3]  S. Reed,et al.  Key roles of adjuvants in modern vaccines , 2013, Nature Medicine.

[4]  D. Rao,et al.  Novel adjuvants & delivery vehicles for vaccines development: A road ahead , 2013, The Indian journal of medical research.

[5]  R Geidobler,et al.  Controlled ice nucleation in the field of freeze-drying: fundamentals and technology review. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[6]  Luis A. Brito,et al.  Vaccine adjuvant formulations: a pharmaceutical perspective. , 2013, Seminars in immunology.

[7]  D. Larenas-Linnemann,et al.  Adjuvants for immunotherapy , 2012, Current opinion in allergy and clinical immunology.

[8]  J. Bagan,et al.  Mucoadhesive polymers for oral transmucosal drug delivery: a review. , 2012, Current pharmaceutical design.

[9]  Q. Sattentau,et al.  Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens , 2012, Nature Biotechnology.

[10]  N. Lycke.  Recent progress in mucosal vaccine development: potential and limitations , 2012, Nature Reviews Immunology.

[11]  S. Kim,et al.  Mucosal vaccine adjuvants update , 2012, Clinical and experimental vaccine research.

[12]  M. Rose,et al.  Mucosal immunity and nasal influenza vaccination , 2012, Expert review of vaccines.

[13]  N. Dendouga,et al.  Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. , 2012, Vaccine.

[14]  R. Compans,et al.  Novel vaccines against influenza viruses. , 2011, Virus research.

[15]  D. W. Kim,et al.  Sublingual Immunization with M2-Based Vaccine Induces Broad Protective Immunity against Influenza , 2011, PloS one.

[16]  R. Webster,et al.  Impact of prior seasonal influenza vaccination and infection on pandemic A (H1N1) influenza virus replication in ferrets. , 2011, Vaccine.

[17]  P. Livingston,et al.  Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer , 2011, Expert review of vaccines.

[18]  F. Fang,et al.  Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant. , 2010, Vaccine.

[19]  Mark R. Soboleski,et al.  Single-Dose Mucosal Immunization with a Candidate Universal Influenza Vaccine Provides Rapid Protection from Virulent H5N1, H3N2 and H1N1 Viruses , 2010, PloS one.

[20]  C. Davis,et al.  Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. , 2010, Virology.

[21]  R. Varadarajan,et al.  Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge , 2010, Proceedings of the National Academy of Sciences.

[22]  Shibo Jiang,et al.  Research and development of universal influenza vaccines. , 2010, Microbes and infection.

[23]  R. Compans,et al.  Virus-Like Particle Vaccine Protects against 2009 H1N1 Pandemic Influenza Virus in Mice , 2010, PloS one.

[24]  Mark R. Soboleski,et al.  Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. , 2009, Vaccine.

[25]  Ying-hua Chen,et al.  The co-administration of CpG-ODN influenced protective activity of influenza M2e vaccine. , 2009, Vaccine.

[26]  Gabriele Neumann,et al.  Emergence and pandemic potential of swine-origin H1N1 influenza virus , 2009, Nature.

[27]  J. Haensler,et al.  Emulsion-based adjuvants for influenza vaccines , 2009, Expert review of vaccines.

[28]  John V Frangioni,et al.  Detection of breast cancer microcalcifications using a dual-modality SPECT/NIR fluorescent probe. , 2008, Journal of the American Chemical Society.

[29]  J. Kwang,et al.  Monoclonal Antibodies against the Fusion Peptide of Hemagglutinin Protect Mice from Lethal Influenza A Virus H5N1 Infection , 2008, Journal of Virology.

[30]  G. Leroux-Roels,et al.  Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. , 2008, Vaccine.

[31]  W. Fiers,et al.  CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. , 2008, Vaccine.

[32]  R. K. Evans,et al.  Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. , 2008, Vaccine.

[33]  K. Schwarz,et al.  Efficient induction of mucosal and systemic immune responses by virus‐like particles administered intranasally: implications for vaccine design , 2008, European journal of immunology.

[34]  Tae Woo Kim,et al.  Oral Administration of High Molecular Mass Poly-γ-Glutamate Induces NK Cell-Mediated Antitumor Immunity1 , 2007, The Journal of Immunology.

[35]  K. Subbarao,et al.  Scientific barriers to developing vaccines against avian influenza viruses , 2007, Nature Reviews Immunology.

[36]  Joerg M. Buescher,et al.  Microbial Biosynthesis of Polyglutamic Acid Biopolymer and Applications in the Biopharmaceutical, Biomedical and Food Industries , 2007, Critical reviews in biotechnology.

[37]  Samir Mitragotri,et al.  Current status and future prospects of needle-free liquid jet injectors , 2006, Nature Reviews Drug Discovery.

[38]  W. Fiers,et al.  The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. , 2006, Vaccine.

[39]  Montakarn Chittchang,et al.  The use of mucoadhesive polymers in buccal drug delivery. , 2005, Advanced drug delivery reviews.

[40]  Asher Zilberstein,et al.  Human T helper (Th) cell lineage commitment is not directly linked to the secretion of IFN‐γ or IL‐4: Characterization of Th cells isolated by FACS based on IFN‐γ and IL‐4 secretion , 2005 .

[41]  J. Spivak.  The anaemia of cancer: death by a thousand cuts , 2005, Nature Reviews Cancer.

[42]  M. Alonso,et al.  Nanoparticles as carriers for nasal vaccine delivery , 2005, Expert review of vaccines.

[43]  S. Fukuyama,et al.  NALT- versus PEYER'S-patch-mediated mucosal immunity , 2004, Nature Reviews Immunology.

[44]  J. Shiver,et al.  Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. , 2004, Vaccine.

[45]  A. Lapedes,et al.  Mapping the Antigenic and Genetic Evolution of Influenza Virus , 2004, Science.

[46]  T. Tumpey,et al.  Protection against lethal influenza virus challenge by RNA interference in vivo. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[47]  Ying-hua Chen,et al.  Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge. , 2004, Immunology letters.

[48]  A. Jegerlehner,et al.  Influenza A Vaccine Based on the Extracellular Domain of M2: Weak Protection Mediated via Antibody-Dependent NK Cell Activity , 2004, The Journal of Immunology.

[49]  N. Valiante,et al.  Recent advances in the discovery and delivery of vaccine adjuvants , 2003, Nature Reviews Drug Discovery.

[50]  C. Gerdil.  The annual production cycle for influenza vaccine. , 2003, Vaccine.

[51]  I. Shih,et al.  The production of poly-(γ-glutamic acid) from microorganisms and its various applications , 2001 .

[52]  K. Okuda,et al.  Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene. , 2001, Vaccine.

[53]  K G Nicholson,et al.  Influenza: vaccination and treatment. , 2001, The European respiratory journal.

[54]  K. Okuda,et al.  Arg-Gingipain A DNA Vaccine Induces Protective Immunity against Infection by Porphyromonas gingivalis in a Murine Model , 2001, Infection and Immunity.

[55]  R. Webster,et al.  Cross-Reactive, Cell-Mediated Immunity and Protection of Chickens from Lethal H5N1 Influenza Virus Infection in Hong Kong Poultry Markets , 2001, Journal of Virology.

[56]  D. Bush,et al.  Determination of baseline human nasal pH and the effect of intranasally administered buffers. , 2000, International journal of pharmaceutics.

[57]  Walter Fiers,et al.  A universal influenza A vaccine based on the extracellular domain of the M2 protein , 1999, Nature Medicine.

[58]  P. Šebo,et al.  Heterosubtypic protection against influenza A induced by adenylate cyclase toxoids delivering conserved HA2 subunit of hemagglutinin. , 2013, Antiviral research.

[59]  I. Stephenson,et al.  Influenza vaccines for the future , 2009 .